BioSpace News Archive

Business

OneFifteen Opens the First of its State-of-the-Art Facilities for the Treatment of Opioid Use Disorder in Dayton, Ohio

OneFifteen, a non-profit ecosystem dedicated to the full and sustained recovery of people living with opioid addiction, is celebrating the opening of the first facilities within its state-of-the-art campus in Dayton, Ohio.

June 14, 2019
·
6 min read
Business

Alexandria Real Estate Equities, Inc., in Partnership With Verily, Leads Design and Development of State-of-the-Art Campus in Support of OneFifteen’s Uniquely Comprehensive Model of Care for Opioid Addiction

OneFifteen celebrates its grand opening in Dayton, Ohio -- a city once known for its rich history of innovation, but now at the center of the national opioid epidemic -- with the goal to reduce opioid overdose deaths and contribute to the vitality and well-being of the community

June 14, 2019
·
5 min read
Drug Development

bluebird bio Presents New Data for LentiGlobin® Gene Therapy for Sickle Cell Disease (SCD) at 24th European Hematology Association (EHA) Congress

In patients who were at least six months post-treatment with LentiGlobin for SCD, median level of abnormal sickle hemoglobin (HbS) was reduced to ≤50 percent of total Hb

June 14, 2019
·
7 min read
Drug Development

bluebird bio Presents Long-Term Efficacy and Safety Data from Clinical Studies of LentiGlobin® Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) at 24th European Hematology Association (EHA) Congress

bluebird bio, Inc. announced updated results from the completed Phase 1/2 Northstar study, and new data from the Phase 3 Northstar-2 and Phase 3 Northstar-3 clinical studies of its LentiGlobin® gene therapy for patients with transfusion-dependent β-thalassemia, at the 24th European Hematology Association Congress in Amsterdam, the Netherlands.

June 14, 2019
·
10 min read
Policy

/R E P E A T -- Notice to the media - Health Canada officials will provide an update on the legalization and regulation of cannabis/

Health Canada officials will hold a media technical briefing regarding the next steps in the legalization and regulation of cannabis.

June 14, 2019
·
1 min read
Drug Development

Enanta Pharmaceuticals Announces Topline Results Showing EDP-938 Achieved its Primary and Secondary Endpoints in its Phase 2a Human Challenge Study in Healthy Adults Infected with Respiratory Syncytial Virus (RSV)

EDP-938 achieved highly statistically significant (p<0.001) reductions in viral load and in resolution of clinical symptoms compared to placebo

June 14, 2019
·
7 min read
Drug Development

BerGenBio Presents Preliminary Phase II Clinical Data at EHA 24: Bemcentinib in Combination With Low Dose Chemotherapy Yields Durable Responses in AML Patients Unfit for Intensive Chemotherapy

BerGenBio ASA presents data showing significant efficacy in a Phase II clinical trial evaluating bemcentinib, a first-in-class selective oral AXL inhibitor, in combination with low-dose cytarabine as a potential new treatment regimen for AML patients unfit for intensive therapy.

June 14, 2019
·
8 min read
Drug Development

Positive Phase 3 Extension Data for ULTOMIRIS® (ravulizumab) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented at European Hematology Association (EHA) Congress

ULTOMIRIS demonstrated consistent efficacy and safety through 52 weeks, with no cases of breakthrough hemolysis (BTH) associated with incomplete C5 complement inhibition

June 14, 2019
·
28 min read
Drug Development

Lilly Presents Positive Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology

Eli Lilly and Company announced that the company will present positive findings from the Phase 3b/4 SPIRIT-Head-to-Head study in patients with active psoriatic arthritis as a late-breaking abstract at the European Congress of Rheumatology in Madrid, Spain on June 15.

June 14, 2019
·
9 min read
Business

Texas Maternal-Fetal Medicine Practice Joins MEDNAX

MEDNAX, Inc., announced its affiliation with Alfredo Gei MD, P.A., a private maternal-fetal medicine practice based in Houston.

June 14, 2019
·
4 min read